Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

698
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
698
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

527
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
527
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

623
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
623

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Geroprotective effects of diet and exercise plus metformin in frail older veterans with obesity: The DEMFOS randomized trial protocol.

Contemporary clinical trials·2026
Same author

Lifestyle Intervention Therapy Modulates Global DNA Methylation and Adipogenic Gene Expression in Severely Obese Hypogonadal Men.

Metabolites·2026
Same author

Testosterone plus lifestyle therapy improves skeletal muscle glycolysis in older men with obesity and hypogonadism.

Frontiers in endocrinology·2026
Same author

Role of Systemic Factors in the Progression to Vision-Threatening Diabetic Retinopathy in a New Mexican Patient Population with Type 2 Diabetes: Glycemic Control Is Not Enough.

Journal of diabetes research·2026
Same author

Correction to: High-Fidelity Finite Element Modeling Technique to Improve Sensitivity to Bone Tissue Changes of Older Adults with Obesity undergoing Intensive Lifestyle Intervention.

Annals of biomedical engineering·2026
Same author

Perceptibility of AI-revised content in pharmacy residency letters of intent.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025

Related Experiment Video

Updated: Aug 26, 2025

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.5K

Baseline 10-2 Visual Field Loss as a Predictor for Future Glaucoma Progression.

Michael Sullivan-Mee1,2, Bryan Kimura1, Helen Kee1

  • 1Eye Clinic Raymond G. Murphy VA Medical Center.

Journal of Glaucoma
|October 12, 2022
PubMed
Summary

Baseline 10-2 visual field (VF) loss is the strongest predictor of future 24-2 VF loss in glaucoma patients. Incorporating 10-2 VF testing may improve glaucoma risk analysis and prediction of disease progression.

More Related Videos

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.4K
Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss
07:12

Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss

Published on: April 11, 2025

527

Related Experiment Videos

Last Updated: Aug 26, 2025

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.5K
Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.4K
Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss
07:12

Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss

Published on: April 11, 2025

527

Area of Science:

  • Ophthalmology
  • Glaucoma Research
  • Visual Field Testing

Background:

  • Glaucoma is a leading cause of irreversible blindness.
  • Accurate prediction of glaucoma progression is crucial for timely intervention.
  • Standard 24-2 visual field (VF) testing is widely used, but its predictive limitations are being explored.

Purpose of the Study:

  • To investigate the relationship between baseline 10-2 VF loss and subsequent 24-2 VF loss in glaucoma patients.
  • To determine if 10-2 VF testing improves the prediction of glaucoma progression compared to 24-2 VF testing alone.

Main Methods:

  • A prospective longitudinal study was conducted with 202 subjects (394 eyes) at a VA Medical Center.
  • Subjects underwent at least 5 quality 24-2 VF tests over 3 years, with testing every 4-6 months.
  • Mixed model regression and Cox Proportional Hazard regression analyses identified predictors of 24-2 VF mean deviation change rate and new VF loss events.

Main Results:

  • The presence of baseline 10-2 VF defect was the strongest predictor of faster 24-2 VF loss rate.
  • Including 10-2 VF variables significantly improved the predictive capability of regression models.
  • Eyes with baseline 10-2 VF loss had a 22-fold greater risk of developing future VF loss events.

Conclusions:

  • Baseline 10-2 VF defect is a highly effective predictor of subsequent 24-2 VF progression.
  • 10-2 VF testing provides unique value in predicting future glaucoma progression.
  • Integrating 10-2 VF testing into baseline glaucoma risk analysis is recommended.